Published in Blood on August 01, 2002
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res (2010) 1.15
ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan. Genet Test Mol Biomarkers (2012) 0.81
Fluid biopsy for solid tumors: a patient's companion for lifelong characterization of their disease. Future Oncol (2012) 0.76
Evolutionary dynamics of two related malignant plasma cell lines. Cell Cycle (2010) 0.75
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med (2003) 3.93
Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood (2005) 3.71
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood (2013) 3.23
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med (2002) 3.08
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood (2003) 2.60
A quantitative measurement of the human somatic mutation rate. Cancer Res (2005) 2.55
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.36
Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res (2007) 2.08
In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood (2010) 1.98
Ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2. Exp Cell Res (2003) 1.78
Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J (2012) 1.76
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood (2002) 1.72
Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res (2003) 1.64
Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. Leuk Res (2011) 1.63
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood (2009) 1.59
Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle (2006) 1.43
LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis. Dev Cell (2009) 1.39
A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood (2009) 1.36
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res (2005) 1.35
Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin Cancer Res (2009) 1.33
Maternally transmitted severe glucose 6-phosphate dehydrogenase deficiency is an embryonic lethal. EMBO J (2002) 1.30
Glucose 6-phosphate dehydrogenase deficiency: from genotype to phenotype. Haematologica (2006) 1.24
Replicative aging and gene expression in long-term cultures of human bone marrow stromal cells. Tissue Eng (2002) 1.19
The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood (2007) 1.17
Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. Blood (2012) 1.16
The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (2006) 1.15
Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia. FEBS Lett (2007) 1.06
Neutral evolution in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (2008) 1.05
BCR-ABL in chronic myelogenous leukemia--how does it work? Acta Haematol (2008) 1.05
Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica (2013) 1.04
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharmacol (2009) 1.04
Paroxysmal nocturnal hemoglobinuria and eculizumab. Haematologica (2010) 1.00
A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res (2005) 0.99
Severe telomere shortening in patients with paroxysmal nocturnal hemoglobinuria affects both GPI- and GPI+ hematopoiesis. Blood (2003) 0.99
Transcriptional functionality of germ line p53 mutants influences cancer phenotype. Clin Cancer Res (2007) 0.99
Glycosylphosphatidylinositol-linked proteins are required for maintenance of a normal peripheral lymphoid compartment but not for lymphocyte development. Eur J Immunol (2002) 0.98
Natural course and biology of CML. Ann Hematol (2015) 0.98
Glycosylphosphatidylinositol-specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria. Blood (2013) 0.98
Mechanisms of resistance to BCR-ABL kinase inhibitors. Leuk Lymphoma (2011) 0.97
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood (2003) 0.96
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol Cancer Res (2002) 0.96
Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int J Hematol (2004) 0.96
Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells. PLoS One (2012) 0.95
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood (2011) 0.94
Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene (2005) 0.94
Highly homologous T-cell receptor beta sequences support a common target for autoreactive T cells in most patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 0.94
CD157 is an important mediator of neutrophil adhesion and migration. Blood (2004) 0.94
Analysis of gene expression profiles reveals novel correlations with the clinical course of colorectal cancer. Oncol Res (2007) 0.94
The use of PIG-A as a sentinel gene for the study of the somatic mutation rate and of mutagenic agents in vivo. Mutat Res (2009) 0.93
Pregnancy in PNH: another eculizumab baby. Br J Haematol (2010) 0.93
Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood (2002) 0.93
Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. Blood (2005) 0.93
Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematol (2002) 0.92
High incidence of thrombosis in African-American and Latin-American patients with Paroxysmal Nocturnal Haemoglobinuria. Thromb Haemost (2005) 0.91
CD157 plays a pivotal role in neutrophil transendothelial migration. Blood (2006) 0.91
In vivo gene marking of rhesus macaque long-term repopulating hematopoietic cells using a VSV-G pseudotyped versus amphotropic oncoretroviral vector. J Gene Med (2004) 0.90
Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. Blood (2002) 0.89
Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. Blood (2002) 0.89
Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab. N Engl J Med (2010) 0.88
A Role for PML in Innate Immunity. Genes Cancer (2011) 0.88
Feasibility of evaluating quality cancer care using registry data and electronic health records: a population-based study. Int J Qual Health Care (2012) 0.88
Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature. Haematologica (2011) 0.87
Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient. Br J Haematol (2011) 0.87
Selective splenic artery embolization for the treatment of thrombocytopenia and hypersplenism in paroxysmal nocturnal hemoglobinuria. J Hematol Oncol (2014) 0.87
The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia. Mol Biotechnol (2007) 0.86
Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571. Br J Haematol (2002) 0.86
Two founder mutations in the SEC23B gene account for the relatively high frequency of CDA II in the Italian population. Am J Hematol (2011) 0.86
BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia. Br J Haematol (2012) 0.85
Somatic mutations and the hierarchy of hematopoiesis. Bioessays (2010) 0.85
Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol (2003) 0.84
Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines. Cancer (2005) 0.84
Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood (2002) 0.84
Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer. Int J Cancer (2008) 0.83
Haemoglobin's chaperone. Nature (2002) 0.83
Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. Biochem J (2005) 0.83
CD40 and B-cell receptor signalling induce MAPK family members that can either induce or repress Bcl-6 expression. Mol Immunol (2009) 0.83
G6PD is indispensable for erythropoiesis after the embryonic-adult hemoglobin switch. Blood (2004) 0.82
The frequency of granulocytes with spontaneous somatic mutations: a wide distribution in a normal human population. PLoS One (2013) 0.82
Nuclear positioning of the BACH2 gene in BCR-ABL positive leukemic cells. Genes Chromosomes Cancer (2007) 0.82
The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer. Clin Cancer Res (2012) 0.81
Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib. Clin Cancer Res (2006) 0.81
Proteasome proteolytic profile is linked to Bcr-Abl expression. Exp Hematol (2009) 0.81
New Insights into the Pathophysiology of Acquired Cytopenias. Hematology Am Soc Hematol Educ Program (2000) 0.81
Frequency of missense mutations in the coding region of a eukaryotic gene transferred by retroviral vectors. J Virol (2002) 0.80
Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach. Biochim Biophys Acta (2010) 0.80
Expression of Plasmodium falciparum G6PD-6PGL in laboratory parasites and in patient isolates in G6PD-deficient and normal Nigerian children. Br J Haematol (2003) 0.80
Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia. Br J Haematol (2006) 0.79
A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL. PLoS One (2013) 0.79
RUNX1 mutations are rare in chronic phase polycythaemia vera. Br J Haematol (2011) 0.79
Novel compounds with antiproliferative activity against imatinib-resistant cell lines. Mol Cancer Ther (2007) 0.79